Lonza reported a mixed set of condensed 2019 figures, which were below our expectations (EBITDA: -5%) but broadly met consensus based on adjusted figures. The company’s performance was driven by Pharma Biotech & Nutrition while Specialty Ingredients’ profitability was able to broadly absorb the lack of the former Consumer Health & Nutrition business (now reported under Pharma Biotech) and the carve out.
21 Jan 2020
Clear miss in a challenging situation
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Clear miss in a challenging situation
Lonza Group AG (0QNO:LON) | 0 0 0.0% | Mkt Cap: 22,735m
- Published:
21 Jan 2020 -
Author:
Martin Schnee -
Pages:
3
Lonza reported a mixed set of condensed 2019 figures, which were below our expectations (EBITDA: -5%) but broadly met consensus based on adjusted figures. The company’s performance was driven by Pharma Biotech & Nutrition while Specialty Ingredients’ profitability was able to broadly absorb the lack of the former Consumer Health & Nutrition business (now reported under Pharma Biotech) and the carve out.